Your selection
NoneFilter by content type
Filter by form group
Filter by type
Filter by tags
Filter by gallery
Filter by category
Filter by category
Filter by category
Filter by category
Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting
October 19, 2023 - … including Boxed WARNING and Medication Guide . About ADUHELM ® (aducanumab-avwa) ADUHELM (aducanumab-avwa), a human monoclonal antibody, … disease by reducing amyloid beta plaques in the brain. ADUHELM is indicated for the treatment of Alzheimer’s …
Statement on JAMA Neurology Publication about Amyloid-Related Imaging Abnormalities in Two Phase 3 Studies Evaluating Aducanumab in Early Alzheimer’s Disease
November 22, 2021 - … imaging abnormalities (ARIA) in the Phase 3 trials of ADUHELM (aducanumab-avwa). The publication notes that the … imaging abnormalities (ARIA) in the Phase 3 trials of ADUHELM (aducanumab-avwa). … Statement on JAMA Neurology … imaging abnormalities (ARIA) in the Phase 3 trials of ADUHELM (aducanumab-avwa). The publication notes that the …
Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development
November 15, 2021 - … ® (nusinersen), Plegridy ® (peginterferon beta-1a) and Aduhelm™ (aducanumab-avwa). Dr. Sandrock served on Biogen’s … groundbreaking treatment for spinal muscular atrophy, and Aduhelm, the first new treatment for Alzheimer’s disease in … ® (nusinersen), Plegridy ® (peginterferon beta-1a) and Aduhelm™ (aducanumab-avwa). Dr. Sandrock served on Biogen’s …
Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2B Study at Clinical Trials on Alzheimer's Disease (CTAD) Conference
November 11, 2021 - … potential benefits, safety and efficacy of lecanemab and ADUHELM; potential regulatory discussions, submissions and … business and pipeline programs, including lecanemab and ADUHELM; and risks and uncertainties associated with drug … potential benefits, safety and efficacy of lecanemab and ADUHELM; potential regulatory discussions, submissions and …
Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer's Disease Under the Accelerated Approval Pathway
September 27, 2021 - … potential benefits, safety and efficacy of lecanemab and ADUHELM; potential regulatory discussions, submissions and … business and pipeline programs, including lecanemab and ADUHELM; and risks and uncertainties associated with drug … potential benefits, safety and efficacy of lecanemab and ADUHELM; potential regulatory discussions, submissions and …
Eisai Presents Late-Breaker Updates on Lecanemab Clinical, Biomarker and Safety Data from Phase 2B Study Core and Open-Label Extension Across Five Years at Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 10, 2021 - … potential benefits, safety and efficacy of lecanemab and ADUHELM; potential regulatory discussions, submissions and … business and pipeline programs, including lecanemab and ADUHELM; and risks and uncertainties associated with drug … potential benefits, safety and efficacy of lecanemab and ADUHELM; potential regulatory discussions, submissions and …
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
March 8, 2023 - … and advanced science that led to the co-development of ADUHELM and LEQEMBI in Alzheimer’s disease. Caroline has deep … and advanced science that led to the co-development of ADUHELM and LEQEMBI in Alzheimer’s disease. Caroline has deep … and advanced science that led to the co-development of ADUHELM and LEQEMBI in Alzheimer’s disease. Caroline has deep …
Tue, 06/08/2021 - 08:00 - … Biogen ADUHELM Launch Webcast Biogen ADUHELM Launch Webcast Event Type Conference Presentation Listen to webcast Supporting Materials Biogen ADUHELM Launch 4.3 MB Jun 8, 2021 8:00 AM EDT … Biogen …
Biogen Reports First Quarter 2022 Results
May 3, 2022 - … diluted EPS $3.62; EPS negatively impacted by $0.76 due to ADUHELM inventory write-offs … Biogen Reports First Quarter … diluted EPS $3.62; EPS negatively impacted by $0.76 due to ADUHELM inventory write-offs …
